16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

Phase 2 Completed 94 enrolled Akebia Therapeutics

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in participants with end stage renal disease undergoing chronic hemodialysis.

Timeline

Start: 2014-09-10
Primary completion: 2015-07-22
Completion: 2015-07-22

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vadadustat	Small molecule	—	Oral

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

Summary

Timeline

Drugs

Indications